Skip to main content
. Author manuscript; available in PMC: 2019 May 1.
Published in final edited form as: Thromb Res. 2018 Mar 7;165:1–5. doi: 10.1016/j.thromres.2018.03.001

Table 3. Summary of MV TF activity and number of VTE in patients with different types of tumors.

Tumor entity Histopathology (number) Number of VTE MV TF activity (pg/mL), median [IQR] vs healthy controls
Gastrointestinal Adenocarcinoma (n=7) 3 0.35 [0.30-4.67] P=0.033
Prostate Adenocarcinoma (n=5) 0 0.74 [0.22-3.77] P=0.024
Gynecological Adenocarcinoma (n=4) 1 0.33 [0.03-2.74] NS
Pancreas Adenocarcinoma (n=2) 0 0.86 [0.62-1.10] -
Colon Adenocarcinoma (n=11) 2 0.19 [0.03-1.16] NS
Lung Adenocarcinoma (n=6) 2 0.28 [0.10-0.58] NS
Breast Adenocarcinoma (n=10) 1 0.20 [0.07-0.40] NS
Unknown primary Adenocarcinoma (n=1) 0 0.34 -
Melanoma Non-adenocarcinoma (n=3) 0 0 [0-0.01] NS
Glioblastoma Non-adenocarcinoma (n=3) 0 0 [0-0.05] NS
AML Non-adenocarcinoma (n=1) 0 0.59 -
Lung Non-adenocarcinoma (n=1) 0 0.51 -
Lymphoma Non-adenocarcinoma (n=1) 0 0.42 -
Liposarcoma Non-adenocarcinoma (n=1) 0 0.42 -
Sarcoma Non-adenocarcinoma (n=1) 0 0.13 -
Neuroendocrine Non-adenocarcinoma (n=1) 0 0.05 -
Gingival Non-adenocarcinoma (n=1) 1 0 -
Gastrointestinal Non-adenocarcinoma (n=1) 1 0 -